Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | USP9X | Q93008 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12032789 | 0.85 | KDM4E (0.43) | MAPK1KDM4EHSD17B10NPC1RAB9A | |
| SCHEMBL12053508 | 0.82 | KDM4E (0.41) | MAPK1KDM4EHSD17B10NPC1RAB9A | |
| SCHEMBL23512523 | 0.81 | SMN1; SMN2 (0.41) | HSD17B10NPC1RAB9ATLR8TLR7 | |
| SCHEMBL12109837 | 0.78 | MAPK1 (0.40) | MAPK1KDM4EHSD17B10NPC1RAB9A | |
| SCHEMBL21807277 | 0.77 | MAPK1 (0.39) | MAPK1KDM4EHSD17B10NPC1RAB9A | |
| SCHEMBL24616544 | 0.72 | NPC1 (0.38) | MAPK1KDM4EHSD17B10NPC1RAB9A | |
| SCHEMBL24498587 | 0.70 | PKLR (0.33) | — | |
| SCHEMBL12109861 | 0.68 | LMNA (0.42) | MAPK1KDM4EHSD17B10NPC1RAB9A | |
| SCHEMBL24351117 | 0.68 | SMN1; SMN2 (0.45) | HSD17B10NPC1RAB9ATLR8TLR7 | |
| SCHEMBL29343777 | 0.67 | CCR1 (0.39) | RAB9AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023168036-A1 | METHOD OF TREATMENT INCLUDING KRAS G12C INHIBITORS AND SHP2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | 280 Bio, Inc (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, KRAS, HRAS | MAPK1 156/4885KDM4E 3126/4885HSD17B10 3394/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | MAPK1 416/4885KDM4E 3543/4885HSD17B10 3449/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | MAPK1 332/4885KDM4E 3110/4885HSD17B10 4468/4885 |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | NRAS, KRAS, RAB8A | MAPK1 95/4885KDM4E 4407/4885HSD17B10 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.